Sun Pharma's Q1 margins likely to be hit on elevated input costs: Analysts

Sun Pharma Q1FY23 results: Prabhudas Lilladher foresees the company's net profit to rise 27 per cent year-on-year (YoY) to Rs 1,786 crores from Rs 1,445 crores in the year-ago quarter.

Drug major Sun Pharmaceutical Industries Ltd is expected to post healthy yearly revenues in the April-June quarter (Q1FY23) to Rs 10,383 crores from Rs 9,719 crores last year, according to an average of five brokerage estimates. The firm will release its Q1FY23 results on Friday, July 29.

The steady revenue is likely on the back of continued robust growth in the company’s specialty portfolio, supported by decent growth in domestic formulations too, analysts said.   
 

However, the firm is expected to report a decline in operating profits and consequently lower margins due to price erosion in the US, and elevated